此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus

2013年4月10日 更新者:Gynecologic Oncology Group

A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus sargramostim in treating patients who have advanced, persistent, or recurrent cancer of the uterus.

研究概览

详细说明

OBJECTIVES:

  • Determine the antitumor activity of dacarbazine, mitomycin, doxorubicin, and cisplatin plus sargramostim (GM-CSF) in patients with advanced, persistent, or recurrent leiomyosarcoma of the uterus.
  • Determine the nature and degree of toxicity of this regimen in these patients.

OUTLINE: Patients receive dacarbazine IV over 2 hours, followed by mitomycin IV over 2-5 minutes, doxorubicin IV over 2-5 minutes, and cisplatin IV over 2 hours on day 1. Patients also receive sargramostim (GM-CSF) subcutaneously (SC) once every 12 hours on days -6 to -3 before the first chemotherapy course and then on days 2-15 and 23-26 of all chemotherapy courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease receive a maximum of 4 courses. Patients achieving complete or partial response receive a maximum of 6 courses.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 12-43 patients will be accrued for this study within 12-28 months.

研究类型

介入性

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Oslo、挪威、N-0310
        • Norwegian Radium Hospital
    • California
      • Los Angeles、California、美国、90095-1781
        • Jonsson Comprehensive Cancer Center, UCLA
    • Colorado
      • Denver、Colorado、美国、80010
        • University of Colorado Cancer Center
    • District of Columbia
      • Washington、District of Columbia、美国、20307-5001
        • Walter Reed Army Medical Center
    • Illinois
      • Chicago、Illinois、美国、60612-3864
        • Rush-Presbyterian-St. Luke's Medical Center
    • Iowa
      • Iowa City、Iowa、美国、52242-1009
        • Holden Comprehensive Cancer Center
    • Maryland
      • Bethesda、Maryland、美国、20892-1182
        • Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
    • Massachusetts
      • Boston、Massachusetts、美国、02111
        • Tuft-New England Medical Center
    • Minnesota
      • Rochester、Minnesota、美国、55905-0001
        • Mayo Clinic Cancer Center
    • Missouri
      • Saint Louis、Missouri、美国、63110
        • Washington University School of Medicine
    • New Jersey
      • Camden、New Jersey、美国、08103-1489
        • Cooper University Hospital
    • New York
      • Stony Brook、New York、美国、11794-8091
        • State University of New York Health Sciences Center - Stony Brook
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599-7295
        • Lineberger Comprehensive Cancer Center, UNC
      • Durham、North Carolina、美国、27710
        • Duke Comprehensive Cancer Center
      • Winston-Salem、North Carolina、美国、27157-1065
        • Comprehensive Cancer Center at Wake Forest University
    • Ohio
      • Cincinnati、Ohio、美国、45267-0526
        • Barrett Cancer Center
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73190
        • University of Oklahoma College of Medicine
    • Pennsylvania
      • Abington、Pennsylvania、美国、19001-3788
        • Abington Memorial Hospital
      • Philadelphia、Pennsylvania、美国、19104-4283
        • University of Pennsylvania Cancer Center
    • Texas
      • Galveston、Texas、美国、77555-0587
        • University of Texas Medical Branch
    • Washington
      • Tacoma、Washington、美国、98405
        • Tacoma General Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

DISEASE CHARACTERISTICS:

  • Histologically confirmed primary leiomyosarcoma (LMS) of the uterus

    • Advanced, persistent, or recurrent disease that is refractory to curative therapy or established treatments
  • At least 1 unidimensionally measurable target lesion

    • At least 20 mm by conventional techniques (e.g., palpation, plain x-ray, CT scan, or MRI) OR
    • At least 10 mm by spiral CT scan
    • Tumors within a previously irradiated field are designated as non-target lesions
  • Ineligible for a higher priority Gynecologic Oncology Group protocol (if one exists), including any active phase III protocol for the same population

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • GOG 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3

Hepatic:

  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • SGOT no greater than 2.5 times ULN
  • Alkaline phosphatase no greater than 2.5 times ULN

Renal:

  • Creatinine no greater than 1.5 times ULN

Other:

  • No active infection requiring antibiotics
  • No grade 2 or greater sensory or motor neuropathy
  • No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • No prior cytotoxic chemotherapy for LMS of the uterus

Endocrine therapy:

  • At least 1 week since prior hormonal therapy for LMS of the uterus
  • Concurrent hormone replacement therapy allowed

Radiotherapy:

  • See Disease Characteristics
  • Recovered from prior recent radiotherapy

Surgery:

  • Recovered from prior recent surgery

Other:

  • Recovered from other prior recent therapy
  • No prior cancer treatment that would preclude study therapy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2002年3月1日

初级完成 (实际的)

2005年10月1日

研究注册日期

首次提交

2002年4月9日

首先提交符合 QC 标准的

2003年1月26日

首次发布 (估计)

2003年1月27日

研究记录更新

最后更新发布 (估计)

2013年4月11日

上次提交的符合 QC 标准的更新

2013年4月10日

最后验证

2004年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅